221 related articles for article (PubMed ID: 18281594)
1. First in vivo evidence for a functional interaction between chemokine and cannabinoid systems in the brain.
Benamar K; Geller EB; Adler MW
J Pharmacol Exp Ther; 2008 May; 325(2):641-5. PubMed ID: 18281594
[TBL] [Abstract][Full Text] [Related]
2. CB1 receptor activation in the basolateral amygdala produces antinociception in animal models of acute and tonic nociception.
Hasanein P; Parviz M; Keshavarz M; Javanmardi K
Clin Exp Pharmacol Physiol; 2007; 34(5-6):439-49. PubMed ID: 17439413
[TBL] [Abstract][Full Text] [Related]
3. CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one]-induced hypothermia.
Rawls SM; Cabassa J; Geller EB; Adler MW
J Pharmacol Exp Ther; 2002 Jun; 301(3):963-8. PubMed ID: 12023525
[TBL] [Abstract][Full Text] [Related]
4. Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons.
Liu Q; Bhat M; Bowen WD; Cheng J
J Pharmacol Exp Ther; 2009 Dec; 331(3):1062-70. PubMed ID: 19752241
[TBL] [Abstract][Full Text] [Related]
5. A novel role of cannabinoids: implication in the fever induced by bacterial lipopolysaccharide.
Benamar K; Yondorf M; Meissler JJ; Geller EB; Tallarida RJ; Eisenstein TK; Adler MW
J Pharmacol Exp Ther; 2007 Mar; 320(3):1127-33. PubMed ID: 17194800
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid CB(2) receptor activation prevents bronchoconstriction and airway oedema in a model of gastro-oesophageal reflux.
Cui YY; D'Agostino B; Risse PA; Marrocco G; Naline E; Zhang Y; Chen HZ; Finance O; Rinaldi-Carmona M; Rossi F; Advenier C
Eur J Pharmacol; 2007 Nov; 573(1-3):206-13. PubMed ID: 17643417
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoid receptor agonists inhibit Ca(2+) influx to synaptosomes from rat brain.
Yoshihara S; Morimoto H; Ohori M; Yamada Y; Abe T; Arisaka O
Pharmacology; 2006; 76(4):157-62. PubMed ID: 16446560
[TBL] [Abstract][Full Text] [Related]
8. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
9. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats.
Izzo AA; Mascolo N; Pinto L; Capasso R; Capasso F
Eur J Pharmacol; 1999 Nov; 384(1):37-42. PubMed ID: 10611417
[TBL] [Abstract][Full Text] [Related]
10. Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.
McCollum L; Howlett AC; Mukhopadhyay S
J Pharmacol Exp Ther; 2007 Jun; 321(3):930-7. PubMed ID: 17379772
[TBL] [Abstract][Full Text] [Related]
11. Physiological evidence for interaction between the HIV-1 co-receptor CXCR4 and the cannabinoid system in the brain.
Benamar K; Yondorf M; Geller EB; Eisenstein TK; Adler MW
Br J Pharmacol; 2009 Aug; 157(7):1225-31. PubMed ID: 19558543
[TBL] [Abstract][Full Text] [Related]
12. Non-opioid antinociception produced by brain stem injections of improgan: significance of local, but not cross-regional, cannabinoid mechanisms.
Hough LB; Svokos K; Nalwalk JW
Brain Res; 2009 Jan; 1247():62-70. PubMed ID: 18983834
[TBL] [Abstract][Full Text] [Related]
13. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2.
Darmani NA
Eur J Pharmacol; 2001 Oct; 430(1):49-58. PubMed ID: 11698062
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid receptor agonists inhibit sensory nerve activation in guinea pig airways.
Yoshihara S; Morimoto H; Yamada Y; Abe T; Arisaka O
Am J Respir Crit Care Med; 2004 Nov; 170(9):941-6. PubMed ID: 15306537
[TBL] [Abstract][Full Text] [Related]
15. Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase.
Naidu PS; Kinsey SG; Guo TL; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2010 Jul; 334(1):182-90. PubMed ID: 20375198
[TBL] [Abstract][Full Text] [Related]
16. Periaqueductal grey CB1 cannabinoid and metabotropic glutamate subtype 5 receptors modulate changes in rostral ventromedial medulla neuronal activities induced by subcutaneous formalin in the rat.
de Novellis V; Mariani L; Palazzo E; Vita D; Marabese I; Scafuro M; Rossi F; Maione S
Neuroscience; 2005; 134(1):269-81. PubMed ID: 15953687
[TBL] [Abstract][Full Text] [Related]
17. Changes in cannabinoid receptor subtype 1 activity and interaction with metabotropic glutamate subtype 5 receptors in the periaqueductal gray-rostral ventromedial medulla pathway in a rodent neuropathic pain model.
Palazzo E; Luongo L; Bellini G; Guida F; Marabese I; Boccella S; Rossi F; Maione S; de Novellis V
CNS Neurol Disord Drug Targets; 2012 Mar; 11(2):148-61. PubMed ID: 22483283
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells.
Ihenetu K; Molleman A; Parsons M; Whelan C
Eur J Pharmacol; 2003 Mar; 464(2-3):207-15. PubMed ID: 12620515
[TBL] [Abstract][Full Text] [Related]
19. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system.
Griffin G; Wray EJ; Tao Q; McAllister SD; Rorrer WK; Aung MM; Martin BR; Abood ME
Eur J Pharmacol; 1999 Jul; 377(1):117-25. PubMed ID: 10448934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
